ORASURE TECHNOLOGIES, INC Deferred Revenue Recognized
ORASURE TECHNOLOGIES, INC (OSUR) reported Deferred Revenue Recognized of $529.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-11-05
- ORASURE TECHNOLOGIES, INC contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $529.00K.
- ORASURE TECHNOLOGIES, INC contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $2.10M, a 35.13% increase year-over-year.
- ORASURE TECHNOLOGIES, INC contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $1.56M.
- ORASURE TECHNOLOGIES, INC contract with customer, liability, revenue recognized for the quarter ending 2023-09-30 was $171.00K.
- ORASURE TECHNOLOGIES, INC contract with customer, liability, revenue recognized for fiscal 2018 was $0.00.
- ORASURE TECHNOLOGIES, INC contract with customer, liability, revenue recognized for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- ORASURE TECHNOLOGIES, INC contract with customer, liability, revenue recognized for fiscal 2016 was $18.95M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|
| 2025-09-30 | $529.00K 10-Q · filed 2025-11-05 | $1.99M 10-Q · filed 2025-11-05 | |
| 2025-03-31 | $2.10M 10-Q · filed 2025-05-07 | ||
| 2024-12-31 | $771.00K 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | $1.36M 10-Q · filed 2025-11-05 | ||
| 2024-03-31 | $1.56M 10-Q · filed 2025-05-07 | ||
| 2023-12-31 | $723.00K 10-Q · filed 2025-05-07 | ||
| 2023-09-30 | $171.00K 10-Q · filed 2025-11-05 | ||
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 | ||
| 2016-12-31 | $18.95M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |